Predictive value of interferon-γ release assays for incident active tuberculosis: A systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 12, Issue 1, 2012, Pages 45-55

  Rangaka, Molebogeng X ^a,b   Wilkinson, Katalin A ^a,c   Glynn, Judith R ^b   Ling, Daphne ^e   Menzies, Dick ^e   Mwansa Kambafwile, Judith ^a   Fielding, Katherine ^b   Wilkinson, Robert J ^a,c,d   Pai, Madhukar ^e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; EMBASE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; MEDLINE; META ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUBERCULIN TEST; TUBERCULOSIS;

DISEASE PROGRESSION; HUMANS; INCIDENCE; INTERFERON-GAMMA RELEASE TESTS; PREDICTIVE VALUE OF TESTS; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 84155167714     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70210-9     Document Type: Article

References (62)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC Consensus statement: global burden of tuberculosis-estimated incidence, prevalence, and mortality by country (WHO global surveillance and monitoring project). JAMA 1999, 282:677-686.
2. Woldehanna S, Volmink J Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004, 1. CD000171.
3. Diel R, Loddenkemper R, Nienhaus A Evidence-based comparison of commercial interferon-gamma release assays for detecting active tuberculosis: a metaanalysis. Chest 2009, 137:952-968.
4. Pai M, Riley LW, Colford JM Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004, 4:761-776.
5. Pai M, Zwerling A, Menzies D Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184.
6. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 2011, published online Jan 12. 10.1136/thx.2010.143180.
7. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011, 56:230-238.
8. Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon-gamma release assays for active pulmonary TB diagnosis in low-and middle-income countries: systematic review and meta-analysis. J Infect Dis (in press).
9. Denkinger CM, Dheda K, Pai M Guidelines on interferon-gamma release assays for tuberculosis infection: concordance, discordance or confusion?. Clin Microbiol Infect 2011, 17:806-814.
10. Comstock GW, Livesay VT, Woolpert SF The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974, 99:131-138.
11. Jeyakumar D Tuberculin reactivity and subsequent development of tuberculosis in a cohort of student nurses. Med J Malaysia 1999, 54:492-495.
12. Leung CC, Yew WW, Chang KC, et al. Risk of active tuberculosis among schoolchildren in Hong Kong. Arch Pediatr Adolesc Med 2006, 160:247-251.
13. Watkins RE, Brennan R, Plant AJ Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis 2000, 4:895-903.
14. Ferebee SH Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970, 26:28-106.
15. Samandari TAT, Nyirenda S, Tedla Z, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 377:1588-1598.
16. Wells GAOCD, Pertersen J, Welch V, Losos M, Tugwell P The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies and meta-analyses (accessed Feb 20, 2010). http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
17. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:25.
18. DerSimonian R, Laird N Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
19. Sheehe PR Combination of log relative risk in retrospective studies of disease. Am J Public Health Nations Health 1966, 56:1745-1750.
20. Higgins JP, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
22. Country Classification World Bank, (accessed Feb 15, 2010). http://data.worldbank.org/about/country-classifications.
23. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008, 336:1106-1110. 17
24. Sterne JA Meta-analysis in Stata: an updated collection from the Stata journal 2009, Stata Press, Atlanta.
25. Moher D, Liberati A, Tetzlaff J, Altman DG Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6. 21; e1000097.
26. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009, 48:954-962.
27. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 2008, 149:777-787.
28. del Corral H, Paris SC, Marin ND, et al. IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One 2009, 4:e8257.
29. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A Negative and positive predictive value of a whole-blood interferon-{gamma} release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011, 183:88-95.
30. Doherty TM, Demissie A, Olobo J, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002, 40:704-706.
31. Harstad I, Winje BA, Heldal E, Oftung F, Jacobsen GW Predictive values of QuantiFERON-TB Gold testing in screening for tuberculosis disease in asylum seekers. Int J Tuberc Lung Dis 2010, 14:1209-1211.
32. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 2008, 3:e1379.
33. Jonnalagadda S, Lohman Payne B, Brown E, et al. Latent tuberculosis detection by interferon gamma release assay during pregnancy predicts active tuberculosis and mortality in human immunodeficiency virus type 1-infected women and their children. J Infect Dis 2010, 202:1826-1835.
34. Joshi R, Narang U, Zwerling A, et al. Predictive value of latent TB tests in Indian health-care workers: a cohort study. Eur Respir J (in press).
35. Kik SV, Franken WP, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010, 35:1346-1353.
36. Leung CC, Yam WC, Yew WW, et al. T-Spot TB outperforms tuberculin skin test in predicting tuberculosis disease. AJRCCM 2010, 182:834-840.
37. Lienhardt C, Fielding K, Hane AA, et al. Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One 2010, 5:e10508.
38. Mahomed H, Hawkridge T, Verver S, et al. The tuberculin skin test versus QuantiFERON TB Gold in predicting tuberculosis disease in an adolescent cohort study. PLoS One 2011, 6:e17984.
39. Yoshiyama T, Harada N, Higuchi K, Sekiya Y, Uchimura K Use of the QuantiFERON TB Gold Test for screening tuberculosis contacts and predicting active disease. Int J Tuberc Lung Dis 2010, 14:819-827.
40. Costa JTSR, Ringshausen F, Nienhaus A Screening for tuberculosis and prediction of disease in Portuguese healthcare workers. J Occup Med Toxicol 2011, 6:19.
41. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008, 177:1164-1170.
42. Haldar P Contact screening with single-step TIGRA testing and risk of active TB infection: the Leicester cohort. Thorax 2009, 64(suppl 4):A5-A74.
43. Santin M, Casas S, Saumoy M, et al. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-gamma release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagn Microbiol Infect Dis 2011, 69:59-65.
44. Pai M, O'Brien R Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions?. PLoS Med 2007, 4:e208.
45. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med 2011, 8:e1001012.
46. Oostenbrink R, Moons KG, Bleeker SE, Moll HA, Grobbee DE Diagnostic research on routine care data: prospects and problems. J Clin Epidemiol 2003, 56:501-506.
47. Greenland P When is a new prediction marker useful? a consideration of lipoprotein-associated phospholipase Ax and C-reactive protein for stroke risk. Arch Intern Med 2005, 165:2454-2456.
48. Kattan MW Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003, 95:634-635.
49. Wald NJ, Hackshaw AK, Frost CD When can a risk factor be used as a worthwhile screening test?. BMJ 1999, 319:1562-1565.
50. Ware JH The limitations of risk factors as prognostic tools. N Engl J Med 2006, 355:2615-2617.
51. Cook NR Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008, 54:17-23.
52. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159:882-890.
53. Dockrell HM Gamma-interferon key, but not sufficient for protection against TB?. Microbiology Today 2007, 172-175.
54. Barry CE, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
55. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M tuberculosis? A TBNET consensus statement. Eur Respir J 2009, 33:956-973.
56. Moons KG, Biesheuvel CJ, Grobbee DE Test research versus diagnostic research. Clin Chem 2004, 50:436-473.
57. Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 2008, 12:498-505.
58. Pai M Spectrum of latent tuberculosis-existing tests cannot resolve the underlying phenotypes. Nat Rev Microbiol 2010, 8:242.
59. Andersen P, Doherty TM, Pai M, Weldingh K The prognosis of latent tuberculosis: can disease be predicted?. Trends Mol Med 2007, 13:175-182.
60. Rangaka MX, Boulle A, van Cutsem G, et al. Isoniazid preventive therapy plus combined antiretroviral therapy to prevent tuberculosis in HIV-infected persons (ART-IPT Study): a pragmatic randomized trial (accessed Aug 10, 2011). http://www.thelancet.com/protocol-reviews/09PRT-2885.
61. Report of the tenth meeting: diagnostic policies 2010, STAG-TB, World Health Organization, Geneva.
62. The global plan to stop TB (2011-2015) 2011, Stop TB partnership, World Health Organization, Geneva.